Souhaitez-vous accéder aux communiqués récents ?

ALK’s new tree SLIT-tablet, ITULAZAX®, has been launched in its first market: GermanyTree pollen allergy is highly prevalent in northern Europe, making Germany a key market for the productIn trials,...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) indberetter hermed følgende transaktioner: 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnHenrik...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions: 1.Details of the person discharging managerial responsibility / person closely associateda)NameHenrik...

Bemærk venligst, at rapporten udelukkende findes på engelsk. Upgraded financial outlook and on track to deliver double-digit growth (unaudited)In Q2, ALK continued to deliver on its strategy, with...

Upgraded financial outlook and on track to deliver double-digit growth (unaudited) In Q2, ALK continued to deliver on its strategy, with broad-based growth across all regions and further strong...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddelte i dag, at virksomheden opjusterer forventningerne til regnskabsåret 2019 baseret på et bedre end forventet resultat for første halvår samt...

                ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the company has revised its 2019 financial guidance upwards based on the better than expected results in the first...

ALK's (ALKB:DC / OMX: ALK B / AKABY / AKBLF) nye anafylaksi-strategi er at blive en betydelig aktør på det amerikanske adrenalinmarked baseret på en eksklusivaftale med Windgap Medical om lancering af...

ALK's (ALKB:DC / OMX: ALK B / AKABY / AKBLF) new anaphylaxis strategy is to become a major player in the US epinephrine market based on an exclusive deal with Windgap Medical to launch a next...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2019 tirsdag den 13. august 2019. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for...